146 related articles for article (PubMed ID: 35080187)
1. A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion.
Di W; Yue C; Ziran Z; Jie Z; Jun N; Ling D; Weiheng H; Xiaoling C; Xiangjuan M; Guangming T; Jindi H; Sen H; Yang W; Jieran L; Jian F
Future Oncol; 2022 Feb; 18(6):669-677. PubMed ID: 35080187
[No Abstract] [Full Text] [Related]
2. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.
Nie K; Zhang Z; You Y; Zhuang X; Zhang C; Ji Y
Thorac Cancer; 2020 Jan; 11(1):8-14. PubMed ID: 31726490
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
6. Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more.
Chen D; Song X; Zhang Y; Kong L; Wang H; Yu J
Future Oncol; 2018 Sep; 14(21):2131-2138. PubMed ID: 29546764
[TBL] [Abstract][Full Text] [Related]
7. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers.
Sabang RL; Gandhiraj D; Fanucchi M; Epelbaum O
Expert Rev Respir Med; 2018 Feb; 12(2):87-94. PubMed ID: 29235400
[TBL] [Abstract][Full Text] [Related]
8. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
10. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
[TBL] [Abstract][Full Text] [Related]
12. Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study.
Dong X; Huang Y; Yi T; Hu C; Gao Q; Chen Y; Zhang J; Chen J; Liu L; Meng R; Zhang S; Dai X; Fei S; Jin Y; Yin P; Hu Y; Wu G
Front Immunol; 2022; 13():1002938. PubMed ID: 36275698
[TBL] [Abstract][Full Text] [Related]
13. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
14. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Yamadori T; Nakao K; Asami K; Yasue T; Otsuka T; Shiroyama T; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Kawase I; Hirashima T
Med Oncol; 2013; 30(3):676. PubMed ID: 23925664
[TBL] [Abstract][Full Text] [Related]
15. The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion.
Wang Z; Zheng Y; Fang Z
Rev Assoc Med Bras (1992); 2018 Mar; 64(3):230-233. PubMed ID: 29641777
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion.
He D; Guo Z; Xie Z; Zhang Y; Deng Q; Yang H
Can Respir J; 2022; 2022():6763625. PubMed ID: 36353447
[TBL] [Abstract][Full Text] [Related]
17. [Progress of Bevacizumab in Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer].
Liu Y; Tian P
Zhongguo Fei Ai Za Zhi; 2019 Feb; 22(2):118-124. PubMed ID: 30827329
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion.
Zeng H; Zhang Y; Tan S; Huang Q; Pu X; Tian P; Li Y
BMC Pulm Med; 2024 Feb; 24(1):89. PubMed ID: 38365707
[TBL] [Abstract][Full Text] [Related]
19. Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.
Marquez-Medina D; Popat S
Clin Transl Oncol; 2016 Aug; 18(8):760-8. PubMed ID: 26680633
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]